{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:07:08Z","timestamp":1781712428841,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-02100-4","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T04:34:39Z","timestamp":1763526879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deep learning model for assessing survival benefits in hepatocellular carcinoma patients undergoing intra-arterial therapies based on proliferative subtype"],"prefix":"10.1038","volume":"8","author":[{"given":"Fei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2100_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2100_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro, J., Ziol, M., Paradis, V. & Zucman-Rossi, J. Molecular and histological correlations in liver cancer. J. Hepatol. 71, 616\u2013630 (2019).","journal-title":"J. Hepatol."},{"key":"2100_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1148\/radiol.2021204352","volume":"300","author":"HJ Kang","year":"2021","unstructured":"Kang, H. J. et al. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology 300, 572\u2013582 (2021).","journal-title":"Radiology"},{"key":"2100_CR4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230457","volume":"308","author":"Y Bao","year":"2023","unstructured":"Bao, Y. et al. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization. Radiology 308, e230457 (2023).","journal-title":"Radiology"},{"key":"2100_CR5","unstructured":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69, 196\u2013216 (2018)."},{"key":"2100_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"2100_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 76, 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li, Q. J. et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J. Clin. Oncol. 40, 150\u2013160 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00259-021-05573-z","volume":"49","author":"C An","year":"2022","unstructured":"An, C. et al. Deep learning radiomics of dual-energy computed tomography for predicting lymph node metastases of pancreatic ductal adenocarcinoma. Eur. J. Nucl. Med. Mol. Imaging 49, 1187\u20131199 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2100_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.coph.2021.07.009","volume":"60","author":"S Mu\u00f1oz-Mart\u00ednez","year":"2021","unstructured":"Mu\u00f1oz-Mart\u00ednez, S., Iserte, G., Sanduzzi-Zamparelli, M., Llarch, N. & Reig, M. Current pharmacological treatment of hepatocellular carcinoma. Curr. Opin. Pharmacol. 60, 141\u2013148 (2021).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2100_CR11","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1706.03762","author":"A Vaswani","year":"2017","unstructured":"Vaswani, A. et al. Atten. Is. All You Need https:\/\/doi.org\/10.48550\/arXiv.1706.03762 (2017).","journal-title":"Atten. Is. All You Need"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng, Z. et al. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J. Clin. Oncol. 41, 117\u2013127 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2100_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He, M. et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 5, 953\u2013960 (2019).","journal-title":"JAMA Oncol."},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","volume":"27","author":"M Ikeda","year":"2016","unstructured":"Ikeda, M. et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann. Oncol. 27, 2090\u2013209 (2016).","journal-title":"Ann. Oncol."},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang, T. Q. et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct. Target Ther. 8, 413 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2100_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000531377","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo, M. et al. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial. Liver Cancer 13, 99\u2013112 (2024).","journal-title":"Liver Cancer"},{"key":"2100_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jvir.2012.12.013","volume":"24","author":"R Golfieri","year":"2013","unstructured":"Golfieri, R. et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension. J. Vasc. Inter. Radio. 24, 509\u2013517 (2013).","journal-title":"J. Vasc. Inter. Radio."},{"key":"2100_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu, N. et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J. Clin. Oncol. 40, 468\u2013480 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2100_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11491-0","volume":"23","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma. BMC Cancer 23, 1026 (2023).","journal-title":"BMC Cancer"},{"key":"2100_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1194200","volume":"13","author":"L Feng","year":"2023","unstructured":"Feng, L., Chen, Q., Huang, L. & Long, L. Radiomics features of computed tomography and magnetic resonance imaging for predicting response to transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis. Front. Oncol. 13, 1194200 (2023).","journal-title":"Front. Oncol."},{"key":"2100_CR21","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1007\/s00330-021-07910-0","volume":"31","author":"C Kong","year":"2021","unstructured":"Kong, C. et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur. Radiol. 31, 7500\u20137511 (2021).","journal-title":"Eur. Radiol."},{"key":"2100_CR22","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1007\/s00432-022-04467-3","volume":"149","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. J. Cancer Res. Clin. Oncol. 149, 5181\u20135192 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2100_CR23","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2589-7500(22)00024-3","volume":"4","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study. Lancet Digital Health 4, e309\u2013e319 (2022).","journal-title":"Lancet Digital Health"},{"key":"2100_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41747-020-00159-0","volume":"4","author":"G Baselli","year":"2020","unstructured":"Baselli, G., Codari, M. & Sardanelli, F. Opening the black box of machine learning in radiology: can the proximity of annotated cases be a way. Eur. Radio. Exp. 4, 30 (2020).","journal-title":"Eur. Radio. Exp."},{"key":"2100_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s11263-019-01228-7","volume":"128","author":"RR Selvaraju","year":"2020","unstructured":"Selvaraju, R. R. et al. Grad-CAM: Visual Explanations from Deep Networks via Gradient-based Localization. Int. J. Comput. Vision 128, 336\u2013359 (2020).","journal-title":"Int. J. Comput. Vision"},{"key":"2100_CR26","doi-asserted-by":"publisher","first-page":"17231","DOI":"10.1007\/s00432-023-05444-0","volume":"149","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 149, 17231\u201317239 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2100_CR27","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.3748\/wjg.v26.i45.7232","volume":"26","author":"H Takaya","year":"2020","unstructured":"Takaya, H. et al. Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. World J. Gastroenterol. 26, 7232\u20137241 (2020).","journal-title":"World J. Gastroenterol."},{"key":"2100_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869993","volume":"13","author":"Q He","year":"2022","unstructured":"He, Q., Yang, J. & Jin, Y. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Front. Immunol. 13, 869993 (2022).","journal-title":"Front. Immunol."},{"key":"2100_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1013248","volume":"13","author":"B Tang","year":"2022","unstructured":"Tang, B. et al. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. Front. Immunol. 13, 1013248 (2022).","journal-title":"Front. Immunol."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02100-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T04:34:41Z","timestamp":1763526881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02100-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02100-4","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"692"}}